Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-09-30
1998-05-05
Lambkin, Deborah
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3138
Patent
active
057475245
ABSTRACT:
mammals. It also discloses novel compounds which are antagonists of the cannabinoid receptors and also discloses pharmaceutical formulations which contain the compounds as an active ingredient.
REFERENCES:
patent: 3331854 (1967-07-01), Huffman et al.
patent: 3448190 (1969-06-01), Baron et al.
patent: 4133814 (1979-01-01), Jones et al.
patent: 4358593 (1982-11-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5223510 (1993-06-01), Gubin et al.
patent: 5308866 (1994-05-01), Lesieur et al.
patent: 5521198 (1996-05-01), Zuckerman
patent: 5534526 (1996-07-01), Culleran
patent: 5552415 (1996-09-01), May
Jones, C., et al., J. Med. Chem., 27: 1057-1066 (1984), "Antiestrogens. 2. Remarkably Effective Estrogen Antagonist with Only Minimal Intrinisic Estrogenicity."
Monge, A., et al., J. Heterocyclic Chem., 22: 1445-1451 (1985), "About the acetate, 2-Indole and 3-Indoleacetohydrazones."
Chambers, M., et al., J. Chem. Soc. Perkin Trans., 1: 1365-1366 (1989), "Nickel Catalysed Conversion of Phenol Triflates into Aromatic Nitriles and Acids."
Durani, N., et al., Indian J. of Chem., 22B: 489-490 (1983), "A Convenient
Jones, C., et al., J. Med. Chem., 35: 931-938 (1992), "Antiestrogens. 3. Estrogen Receptor Affinities and Antiproliferative Effects in MCF-7 Cells of Phenolic Analogues of Trioxifene,
Astoin, J., et al., J. Heterocyclic Chem., 14: 861-869 (1977), "Recherches sur le benzofuranne. LIX. Orientation de l'aroylation de l'ethyl-2 benzofuranne selon la nature du chlorure d'aroyle utilise (1). "
Lynn, A., et al., Journal of Pharmacology and Experimental Therapeutics, 268(3) : pp. 1612-1623 (1993), "Localization of Cannabinoid Receptors and Nonsaturable High-Density Cannabinoid Binding Sites in Peripheral Tissues of the Rat: Implications for Receptor-Mediated Immune Modulation by Cannabinoids".
Mechoulam, R., et al., CNS Drugs, 2(4): pp. 255-260 (1994), "Role and Therapeutic Implications for CNS Disorders".
Mechoulam, R., et al., Biochemical Pharmacology, 48(8): pp. 1537-1544 (1994), "Search for Endogenous Ligands of the Cannabinoid Receptor".
Compton, D., et al., The Journal of Pharmacology and Experimental Therapeutics, 263(3): pp. 1118-1126 (1992), "Aminoalkylindole Analogs: Cannabimimetic Activity of a Class of Compounds Structurally Distinct from .increment..sup.9 -Tetrahydrocannabinol.sup.1 ".
Howlett, A., et al., Tins at Neuroscience, 13: pp. 420-423 (1990), "The cannabinoid receptor: biochemical, anatomical and behavioral characterization".
Felder, C., et al., Proc. Natl. Acad. Sci., 90: pp. 7656-7660 (1993), "Anandamide, an endogenous cannabinoid receptor and stimulates receptor-mediated signal transduction".
Cullinan George J.
Fahey Kennan J.
Koppel Gary A.
Boone David E.
Eli Lilly and Company
Hay Martin A.
Lambkin Deborah
LandOfFree
Cannabinoid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-55167